293 related articles for article (PubMed ID: 17706835)
21. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
Kurzeja M; Rudnicka L; Olszewska M
Am J Clin Dermatol; 2011 Apr; 12(2):113-25. PubMed ID: 21348542
[TBL] [Abstract][Full Text] [Related]
22. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
Longbrake EE; Racke MK
Expert Rev Neurother; 2009 Mar; 9(3):319-21. PubMed ID: 19271940
[TBL] [Abstract][Full Text] [Related]
23. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
Ann N Y Acad Sci; 2011 Mar; 1222():30-9. PubMed ID: 21434940
[TBL] [Abstract][Full Text] [Related]
24. The safety of ustekinumab for the treatment of psoriatic arthritis.
López-Ferrer A; Laiz A; Puig L
Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
[TBL] [Abstract][Full Text] [Related]
25. IL-12-and IL-23 in health and disease.
Croxford AL; Kulig P; Becher B
Cytokine Growth Factor Rev; 2014 Aug; 25(4):415-21. PubMed ID: 25130295
[TBL] [Abstract][Full Text] [Related]
26. Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer.
Quatresooz P; Hermanns-Lê T; Piérard GE; Humbert P; Delvenne P; Piérard-Franchimont C
J Biomed Biotechnol; 2012; 2012():147413. PubMed ID: 22754278
[TBL] [Abstract][Full Text] [Related]
27. The role of interleukin-12 in human infectious diseases: only a faint signature.
Fieschi C; Casanova JL
Eur J Immunol; 2003 Jun; 33(6):1461-4. PubMed ID: 12778462
[TBL] [Abstract][Full Text] [Related]
28. Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy.
Bowman EP; Chackerian AA; Cua DJ
Curr Opin Infect Dis; 2006 Jun; 19(3):245-52. PubMed ID: 16645485
[TBL] [Abstract][Full Text] [Related]
29. Gamma interferon-independent effects of interleukin-12 on immunity to Salmonella enterica serovar Typhimurium.
Price JD; Simpfendorfer KR; Mantena RR; Holden J; Heath WR; van Rooijen N; Strugnell RA; Wijburg OL
Infect Immun; 2007 Dec; 75(12):5753-62. PubMed ID: 17875635
[TBL] [Abstract][Full Text] [Related]
30. Briakinumab for the treatment of plaque psoriasis.
Traczewski P; Rudnicka L
BioDrugs; 2012 Feb; 26(1):9-20. PubMed ID: 22077474
[TBL] [Abstract][Full Text] [Related]
31. Targeting IL-23 in human diseases.
D'Elios MM; Del Prete G; Amedei A
Expert Opin Ther Targets; 2010 Jul; 14(7):759-74. PubMed ID: 20536413
[TBL] [Abstract][Full Text] [Related]
32. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.
Toichi E; Torres G; McCormick TS; Chang T; Mascelli MA; Kauffman CL; Aria N; Gottlieb AB; Everitt DE; Frederick B; Pendley CE; Cooper KD
J Immunol; 2006 Oct; 177(7):4917-26. PubMed ID: 16982934
[TBL] [Abstract][Full Text] [Related]
33. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis.
Yawalkar N; Tscharner GG; Hunger RE; Hassan AS
J Dermatol Sci; 2009 May; 54(2):99-105. PubMed ID: 19264456
[TBL] [Abstract][Full Text] [Related]
34. Early activation of the interleukin-23-17 axis in a murine model of oropharyngeal candidiasis.
Saunus JM; Wagner SA; Matias MA; Hu Y; Zaini ZM; Farah CS
Mol Oral Microbiol; 2010 Oct; 25(5):343-56. PubMed ID: 20883223
[TBL] [Abstract][Full Text] [Related]
35. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
[TBL] [Abstract][Full Text] [Related]
36. Crystal structures of the pro-inflammatory cytokine interleukin-23 and its complex with a high-affinity neutralizing antibody.
Beyer BM; Ingram R; Ramanathan L; Reichert P; Le HV; Madison V; Orth P
J Mol Biol; 2008 Oct; 382(4):942-55. PubMed ID: 18708069
[TBL] [Abstract][Full Text] [Related]
37. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis.
Kauffman CL; Aria N; Toichi E; McCormick TS; Cooper KD; Gottlieb AB; Everitt DE; Frederick B; Zhu Y; Graham MA; Pendley CE; Mascelli MA
J Invest Dermatol; 2004 Dec; 123(6):1037-44. PubMed ID: 15610511
[TBL] [Abstract][Full Text] [Related]
38. The role of IL 23 in the treatment of psoriasis.
Puig L
Expert Rev Clin Immunol; 2017 Jun; 13(6):525-534. PubMed ID: 28165883
[TBL] [Abstract][Full Text] [Related]
39. Anti-IL-12/IL-23p40 antibody ameliorates dermatitis and skin barrier dysfunction in mice with imiquimod-induced psoriasis-like dermatitis.
Takahashi T; Koga Y; Kainoh M
Eur J Pharmacol; 2018 Jun; 828():26-30. PubMed ID: 29544684
[TBL] [Abstract][Full Text] [Related]
40. The role of cytokines in a Porphyromonas gingivalis-induced murine abscess model.
Alayan J; Gemmell E; Ford P; Hamlet S; Bird PS; Ivanovski S; Farah CS
Oral Microbiol Immunol; 2007 Oct; 22(5):304-12. PubMed ID: 17803627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
